P2X and P2Y nucleotide receptors as targets in cardiovascular disease

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 431-449

  Kennedy, Charles ^a   Chootip, Krongkarn ^b   Mitchell, Callum ^a   Syed, Nawazish I Husain ^a,c   Tengah, Asrin ^d  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF THE PUNJAB   (Pakistan)

^d UNIVERSITI BRUNEI DARUSSALAM   (Brunei Darussalam)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; 5 [[(3 PHENOXYBENZYL)(1,2,3,4 TETRAHYDRO 1 NAPHTHYL)AMINO]CARBONYL]TRIMELLITIC ACID; A 740003; A 804598; AF 353; AZ 11645373; MRS 2159; MRS 2220; NF 023; NF 279; NF 449; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR AGONIST; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTERY ENDOTHELIUM; ARTERY MUSCLE; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CONGESTIVE HEART FAILURE; ENDOTHELIUM CELL; HEART INJURY; HEART MUSCLE; HUMAN; HYPERTENSION; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; VASOCONSTRICTION; VASODILATATION; VASOSPASM;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; PURINERGIC P2X RECEPTOR AGONISTS; PURINERGIC P2X RECEPTOR ANTAGONISTS; PURINERGIC P2Y RECEPTOR AGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X; RECEPTORS, PURINERGIC P2Y;

EID: 84875143039     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.6     Document Type: Review

References (151)

1. Burnstock G, Kennedy C. A dual function for adenosine 5́-triphosphate in the regulation of vascular tone. Excitatory cotransmitter with noradrenaline from perivascular nerves and locally released inhibitory intravascular agent. Circ. Res. 58 (3), 319-330 (1986).
2. Kennedy C. Vascular P2-receptors and their possible roles in hypertension. In: Cardiovascular Biology of Purine. Burnstock G, Dobson JG, Liang BT, Linden J (Eds). Kluwer Academic Publishers, Amsterdam, The Netherlands, 243-256 (1998).
3. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 4(1), 1-20 (2008).
4. Burnstock G, Kennedy C. P2X receptors in health and disease. Adv. Pharmacol. 61, 333-372 (2011).
5. Lazarowski ER, Sesma JI, Seminario-Vidal L, Kreda SM. Molecular mechanisms of purine and pyrimidine nucleotide release. Adv. Pharmacol. 61, 221-261 (2011).
6. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ. ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am. J. Physiol. 271(6 Pt 2), H2717-H2722 (1996).
7. Sprague RS, Olearczyk JJ, Spence DM, Stephenson AH, Sprung RW, Lonigro AJ. Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance. Am. J. Physiol. Heart Circ. Physiol. 285(2), H693-H700 (2003).
8. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen. Pharmacol. 16(5), 433-440 (1985).
9. Khakh BS, Burnstock G, Kennedy C et al. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 53(1), 107-118 (2001).
10. Abbracchio MP, Burnstock G, Boeynaems JM et al. International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58(3), 281-341 (2006).
11. Gonzales EB, Kawate T, Gouaux E. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature 460(7255), 599-604 (2009).
12. Kawate T, Michel JC, Birdsong W T, Gouaux E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 460(7255), 592-598 (2009).
13. Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485(7397), 207-212 (2012).
14. Von Kugelgen I, Harden TK. Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv. Pharmacol. 61, 373-415 (2011).
15. Lutz S, Freichel-Blomquist A, Yang Y et al. The guanine nucleotide exchange factor p63RhoGEF, a specifc link between Gq/11-coupled receptor signaling and RhoA. J. Biol. Chem. 280 (12), 11134-11139 (2005).
16. Syed NH, Kennedy, C. Pharmacology of P2X receptors. WIREs Membr. Transp. Signal. 1, 16-30 (2012).
17. Jarvis MF, Khakh BS. ATP-gated P2X cation-channels. Neuropharmacology 56(1), 208-215 (2009).
18. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP. Pharmacology of P2X channels. Pfugers Arch. 452(5), 513-537 (2006).
19. Pintor J, Diaz-Hernandez M, Gualix J, Gomez-Villafuertes R, Hernando F, Miras-Portugal MT. Diadenosine polyphosphate receptors. from rat and guinea-pig brain to human nervous system. Pharmacol. Ther. 87(2-3), 103-115 (2000).
20. Jacobson KA, Kim YC, Wildman SS et al. A pyridoxine cyclic phosphate and its 6-Azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J. Med. Chem. 41(13), 2201-2206 (1998).
21. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87(2), 659-797 (2007).
22. Lambrecht G, Braun K, Damer M et al. Structure-Activity relationships of suramin and pyridoxal-5́-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 8(26), 2371-2399 (2002).
23. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. Pharmacol. 157(7), 1203-1214 (2009).
24. Kim YC, Brown SG, Harden TK et al. Structure-Activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J. Med. Chem. 44(3), 340-349 (2001).
25. Jaime-Figueroa S, Greenhouse R, Padilla F, Dillon MP, Gever JR, Ford AP. Discovery and synthesis of a novel and selective drug-like P2X1 antagonist. Bioorg. Med. Chem. Lett. 15(13), 3292-3295 (2005).
26. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin. Ther. Pat. 20(5), 625-646 (2010).
27. Baqi Y, Hausmann R, Rosefort C, Rettinger J, Schmalzing G, Muller CE. Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. J. Med. Chem. 54(3), 817-830 (2011).
28. Hausmann R, Rettinger J, Gerevich Z et al. The suramin analog 4, 4́, 4́́, 4́́́-(carbonylbis(imino-5, 1, 3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol. Pharmacol. 69(6), 2058-2067 (2006).
29. Donnelly-Roberts D, Mcgaraughty S, Shieh CC, Honore P, Jarvis MF. Painful purinergic receptors. J. Pharmacol. Exp. Ther. 324(2), 409-415 (2008).
30. Jarvis MF, Burgard EC, McGaraughty S et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic infammatory and neuropathic pain in the rat. Proc. Natl Acad. Sci. USA 99(26), 17179-17184 (2002).
31. Ford AP, Gever JR, Nunn PA et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br. J. Pharmacol. 147(Suppl. 2), S132-S143 (2006).
32. Gever JR, Soto R, Henningsen RA et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br. J. Pharmacol. 160 (6), 1387-1398 (2010).
33. Brotherton-Pleiss CE, Dillon MP, Ford AP et al. Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist. Bioorg. Med. Chem. Lett. 20 (3), 1031-1036 (2010).
34. Jones CA, Chessell IP, Simon J et al. Functional characterization of the P2X4 receptor orthologues. Br. J. Pharmacol. 129(2), 388-394 (2000).
35. Wu T, Dai M, Shi XR, Jiang ZG, Nuttall AL. Functional expression of P2X4 receptor in capillary endothelial cells of the cochlear spiral ligament and its role in regulating the capillary diameter. Am. J. Physiol. Heart Circ. Physiol. 301(1), H69-H78 (2011).
36. Guile SD, Alcaraz L, Birkinshaw TN et al. Antagonists of the P2X7 receptor. From lead identifcation to drug development. J. Med. Chem. 52 (10), 3123-3141 (2009).
37. Stokes L, Jiang LH, Alcaraz L et al. Characterization of a selective and potent antagonist of human P2X7 receptors, A Z11645373. Br. J. Pharmacol. 149 (7), 880-887 (2006).
38. Honore P, Donnelly-Roberts D, Namovic MT et al. A-740003 [N-(1-{[(cyanoimino) (5-quinolinylamino) methyl]amino}-2, 2-dimethylpropyl)-2- (3, 4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319(3), 1376-1385 (2006).
39. Nelson DW, Gregg RJ, Kort ME et al. Structure-Activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 49(12), 3659-3666 (2006).
40. Donnelly-Roberts DL, Namovic MT, Surber B et al. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56(1), 223-229 (2009).
41. Broom DC, Matson DJ, Bradshaw E et al. Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-Amino-pyrrolidin-1-yl) methyl]-2-chloro- benzamide, a P2X7 antagonist in animal models of pain and infammation. J. Pharmacol. Exp. Ther. 327(3), 620-633 (2008).
42. 1 receptor. Mol. Pharmacol. 54 (6), 1118-1123 (1998).
43. 6 receptors. J. Med. Chem. 49(24), 7076-7087 (2006).
44. 2 receptor and design of a selective agonist, 2́-Amino- 2́-deoxy-2-thiouridine 5́-triphosphate. J. Med. Chem. 50 (6), 1166-1176 (2007).
45. Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, Harden TK. Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br. J. Pharmacol. 116(1), 1619-1627 (1995).
46. Patel K, Barnes A, Camacho J et al. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. Eur. J. Pharmacol. 430(2-3), 203-210 (2001).
47. Pendergast W, Yerxa BR, Douglass JG 3rd et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5́-polyphosphates. Bioorg. Med. Chem. Lett. 11(2), 157-160 (2001).
48. 2 receptor agonist for the treatment of cystic fbrosis. J. Pharmacol. Exp. Ther. 302(3), 871-880 (2002).
49. 2 receptors. J. Neurosci. 23(17), 6728-6739 (2003).
50. 4 receptor, is an antagonist at the human P2Y(4) receptor. Mol. Pharmacol. 57(5), 926-931 (2000).
51. 2+ ions. Br. J. Pharmacol. 140(7), 1177-1186 (2003).
52. 6 receptor. J. Med. Chem. 49 (18), 5532-5543 (2006).
53. 6 receptor agonists. Bioorg. Med. Chem. 16(12), 6319-6332 (2008).
54. Brunschweiger A, Muller CE. P2 receptors activated by uracil nucleotides-An update. Curr. Med. Chem. 13(3), 289-312 (2006).
55. 6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. J. Biol. Chem. 280 (17), 16909-16915 (2005).
56. 6-receptor agonist. J. Med. Chem. 53(4), 1673-1685 (2010).
57. 6 receptor. Eur. J. Pharmacol. 329(2-3), 231-236 (1997).
58. Chang K, Hanaoka K, Kumada M, Takuwa Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J. Biol. Chem. 270(44), 26152-26158 (1995).
59. Bogdanov Y, Rubino A, Burnstock G. Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. Life Sci. 62(8), 697-703 (1998).
60. 4 nucleotide receptor. Eur. J. Pharmacol. 416(3), 197-202 (2001).
61. 6 nucleotide receptors. Biochem. Pharmacol. 67(9), 1763-1770 (2004).
62. Communi D, Govaerts C, Parmentier M, Boeynaems JM. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272 (51), 31969-31973 (1997).
63. 11 receptor to phospholipase C and adenylyl cyclase. Br. J. Pharmacol. 132(1), 318-326 (2001).
64. 11 receptor antagonists with nanomolar potency. J. Med. Chem. 48(22), 7040-7048 (2005).
65. 11 purinergic receptor in human granulocytes. J. Biol. Chem. 281(42), 31419-31429 (2006).
66. 11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J. Pharmacol. Exp. Ther. 332(1), 238-247 (2010).
67. 12 receptor. J. Pharmacol. Exp. Ther. 331(2), 648-655 (2009).
68. 12. Neuropharmacology 45(1), 145-154 (2003).
69. 12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 17(21), 6013-6018 (2007).
70. James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the frst reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157(4), 599-605 (2009).
71. 13 receptor. Mol. Pharmacol. 64(1), 104-112 (2003).
72. 13 receptor. Biochem. Pharmacol. 70(2), 266-274 (2005).
73. 13 receptor. Biochem. Pharmacol. 68(1), 113-124 (2004).
74. 14 receptor. Mol. Pharmacol. 76(6), 1341-1348 (2009).
75. 14 receptor agonists: truncation of the hexose moiety of uridine-5́-diphosphoglucose and its replacement with alkyl and aryl groups. J. Med. Chem. 53(1), 471-480 (2010).
76. 14 receptor. J. Med. Chem. 50(9), 2030-2039 (2007).
77. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240, 31-304 (2004).
78. Syed NH, Tengah A, Paul A, Kennedy C. Characterisation of P2X receptors expressed in rat pulmonary arteries. Eur. J. Pharmacol. 649(1-3), 342-348 (2010).
79. Kennedy C. The role of purines in the peripheral nervous system. In: Handbook of Experimental Pharmacology 151/1; Purinergic and Pyrimidinergic Signalling I: Molecular, Nervous and Urogenitary System Function., Abbracchio MP, Williams M (Eds). Springer, Heidelberg, Germany, 289-304 (2001).
80. Sneddon P, Burnstock G. ATP as a cotransmitter in rat tail artery. Eur. J. Pharmacol. 106(1), 149-152 (1984).
81. McLaren GJ, Kennedy C, Sneddon P. The effects of suramin on purinergic and noradrenergic neurotransmission in the rat isolated tail artery. Eur. J. Pharmacol. 277(1), 57-61 (1995).
82. Bao JX, Stjarne L. Dual contractile effects of ATP released by feld stimulation revealed by effects of alpha, beta-methylene ATP and suramin in rat tail artery. Br. J. Pharmacol. 110 (4), 1421-1428 (1993).
83. Kennedy C, Saville VL, Burnstock G. The contributions of noradrenaline and ATP to the responses of the rabbit central ear artery to sympathetic nerve stimulation depend on the parameters of stimulation. Eur. J. Pharmacol. 122(3), 291-300 (1986).
84. Ramme D, Regenold JT, Starke K, Busse R, Illes P. Identifcation of the neuroeffector transmitter in jejunal branches of the rabbit mesenteric artery. Naunyn Schmiedebergs Arch. Pharmacol. 336(3), 267-273 (1987).
85. Gitterman DP, Evans RJ. Nerve evoked P2X receptor contractions of rat mesenteric arteries; dependence on vessel size and lack of role of L-type calcium channels and calcium induced calcium release. Br. J. Pharmacol. 132(6), 1201-1208 (2001).
86. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Renal autoregulation in P2X1 knockout mice. Acta Physiol. Scand. 181(4), 445-453 (2004).
87. Mulryan K, Gitterman DP, Lewis CJ et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403(6765), 86-89 (2000).
88. Kennedy C, Burnstock G. ATP produces vasodilation via P1 purinoceptors and vasoconstriction via P2 purinoceptors in the isolated rabbit central ear artery. Blood Vessels 22(3), 145-155 (1985).
89. Kennedy C, Delbro D, Burnstock G. P2-purinoceptors mediate both vasodilation (via the endothelium) and vasoconstriction of the isolated rat femoral artery. Eur. J. Pharmacol. 107(2), 161-168 (1985).
90. Harrington LS, Mitchell JA. Novel role for P2X receptor activation in endothelium-dependent vasodilation. Br. J. Pharmacol. 143 (5), 611-617 (2004).
91. Harrington LS, Evans RJ, Wray J et al. Purinergic 2X1 receptors mediate endothelial dependent vasodilation to ATP. Mol. Pharmacol. 72 (5), 1132-1136 (2007).
92. Bodin P, Bailey D, Burnstock G. Increased fow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells. Br. J. Pharmacol. 103(1), 1203-1205 (1991).
93. 2+ infux into human endothelial cells via P2X4 purinoceptors. Circ. Res. 87(5), 385-391 (2000).
94. Yamamoto K, Sokabe T, Matsumoto T et al. Impaired fow-dependent control of vascular tone and remodeling in P2X4-defcient mice. Nat. Med. 12(1), 133-137 (2006).
95. Hansen MA, Bennett MR, Barden JA. Distribution of purinergic P2X receptors in the rat heart. J. Auton. Nerv. Syst. 78(1), 1-9 (1999).
96. Vassort G. Adenosine 5́-triphosphate: a P2-purinergic agonist in the myocardium. Physiol. Rev. 81(2), 767-806 (2001).
97. Yang R, Liang BT. Cardiac P2X4 receptors: targets in ischemia and heart failure? Circ. Res. 111(4), 397-401 (2012).
98. Hu B, Mei QB, Yao XJ, Smith E, Barry WH, Liang BT. A novel contractile phenotype with cardiac transgenic expression of the human P2X4 receptor. FASEB J. 15(14), 2739-2741 (2001).
99. Shen JB, Pappano AJ, Liang BT. Extracellular ATP-stimulated current in wild-type and P2X4 receptor transgenic mouse ventricular myocytes: implications for a cardiac physiologic role of P2X4 receptors. FASEB J. 20(2), 277-284 (2006).
100. Yang A, Sonin D, Jones L, Barry WH, Liang BT. A benefcial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 287(3), H1096-H1103 (2004).
101. Zhou SY, Mamdani M, Qanud K et al. Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptors. J. Pharmacol. Exp. Ther. 333(3), 920-928 (2010).
102. Musa H, Tellez JO, Chandler NJ et al. P2 purinergic receptor mRNA in rat and human sinoatrial node and other heart regions. Naunyn Schmiedebergs Arch. Pharmacol. 379(6), 541-549 (2009).
103. 2-receptor mRNA levels in congestive heart failure. Life Sci. 65(11), 1195-1206 (1999).
104. Banf C, Ferrario S, De Vincenti O et al. P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death. J. Mol. Cell. Cardiol. 39(6), 929-939 (2005).
105. Vessey DA, Li L, Kelley M. P2X7 receptor agonists pre-And postcondition the heart against ischemia-reperfusion injury by opening pannexin-1/P2X7 channels. Am. J. Physiol. Heart Circ. Physiol. 301(3), H881-H887 (2011).
106. Erlinge D, Harnek J, Van Heusden C, Olivecrona G, Jern S, Lazarowski E. Uridin triphosphate (UTP) is released during cardiac ischemia. Int. J. Cardiol. 100(3), 427-433 (2005).
107. Wee S, Peart JN, Headrick JP. P2 purinoceptor-mediated cardioprotection in ischemic-reperfused mouse heart. J. Pharmacol. Exp. Ther. 323(3), 861-867 (2007).
108. Dolmatova E, Spagnol G, Boassa D et al. Cardiomyocyte ATP release through pannexin 1 aids in early fbroblast activation Am. J. Physiol. Heart Circ. Physiol. 303(10), H1208-H1218 (2012).
109. Vessey DA, Li L, Kelley M. Pannexin-1/P2X7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre-And postconditioning. J. Cardiovasc. Pharmacol. Ther. 15(2), 190-195 (2010).
110. Vessey DA, Li L, Kelley M. Ischemic preconditioning requires opening of pannexin-1/P2X7 channels not only during preconditioning but again after index ischemia at full reperfusion. Mol. Cell. Biochem. 351(1-2), 77-84 (2011).
111. Baroni M, Pizzirani C, Pinotti M et al. Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. FASEB J. 21(8), 1926-1933 (2007).
112. Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J. Clin. Invest. 121(7), 2932-2944 (2011).
113. Di Virgilio F. Liaisons dangereuses: P2X7 and the infammasome. Trends Pharmacol. Sci. 28(9), 465-472 (2007).
114. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 infammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (10), 1170-1178 (2009).
115. Lee BH, Hwang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J. Activation of P2X7 receptor by ATP plays an important role in regulating infammatory responses during acute viral infection. PLoS ONE 7(4), e35812 (2012).
116. Chen JB, Liu WJ, Che H, Liu J, Sun HY, Li GR. Adenosine-5́- triphosphate up-regulates proliferation of human cardiac fbroblasts. Br. J. Pharmacol. 166 (3), 1140-1150 (2012).
117. Kawaguchi M, Takahashi M, Hata T et al. Infammasome activation of cardiac fbroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123(6), 594-604 (2011).
118. Mezzaroma E, Toldo S, Farkas D et al. The infammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl Acad. Sci. USA 108(49), 19725-19730 (2011).
119. Gidlof O, Smith JG, Melander O et al. A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events. PLoS ONE 7(5), e37491 (2012).
120. 1 receptors to disruption of lipid rafts. Biochem. Biophys. Res. Commun. 343(2), 415-419 (2006).
121. Evans RJ, Kennedy C. Characterization of P2-purinoceptors in the smooth muscle of the rat tail artery: a comparison between contractile and electrophysiological responses. Br. J. Pharmacol. 113(3), 853-860 (1994).
122. Kennedy C, Leff P. How should P2X purinoceptors be classifed pharmacologically? Trends Pharmacol. Sci. 16 (5), 168-174 (1995).
123. Robson SC, Sevigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological signifcance. Purinergic Signal. 2(2), 409-430 (2006).
124. Kauffenstein G, Drouin A, Thorin-Trescases N et al. NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc. Res. 85(1), 204-213 (2010).
125. Chootip K, Ness KF, Wang Y, Gurney AM, Kennedy C. Regional variation in P2 receptor expression in the rat pulmonary arterial circulation. Br. J. Pharmacol. 137(5), 637-646 (2002).
126. Chootip K, Gurney AM, Kennedy C. Multiple P2Y receptors couple to calcium-dependent, chloride channels in smooth muscle cells of the rat pulmonary artery. Respir. Res. 6, 124 (2005).
127. 12 receptors in rat intrapulmonary artery using selective ligands. J. Pharmacol. Exp. Ther. 343(3), 755-762 (2012).
128. 12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int. J. Cardiol. 142(2), 187-192 (2010).
129. 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler. Thromb. Vasc. Biol. 24(10), 1810-1815 (2004).
130. Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 42(2), 213-220 (1999).
131. Kubista H, Lechner SG, Wolf AM, Boehm S. Attenuation of the P2Y receptor-mediated control of neuronal Ca2+ channels in PC12 cells by antithrombotic drugs. Br. J. Pharmacol. 138(2), 343-350 (2003).
132. 1 receptor. Mol. Pharmacol. 60(3), 432-439 (2001).
133. 12 receptor. Mol. Pharmacol. 64(5), 1210-1216 (2003).
134. Malmsjo M, Hou M, Harden TK et al. Characterization of contractile P2 receptors in human coronary arteries by use of the stable pyrimidines uridine 5́-O-thiodiphosphate and uridine 5́-O-3-thiotriphosphate. J. Pharmacol. Exp. Ther. 293(3), 755-760 (2000).
135. 14 receptors is a mediator of mast cell degranulation. Biochem. Pharmacol. 79(6), 873-879 (2010).
136. 6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. Mol. Pharmacol. 74 (3), 777-784 (2008).
137. Baek EB, Yoo HY, Park SJ et al. Luminal ATP-induced contraction of rabbit pulmonary arteries and role of purinoceptors in the regulation of pulmonary arterial pressure. Pfugers Arch. 457(2), 281-291 (2008).
138. Dinh-Xuan AT, Higenbottam TW, Clelland CA et al. Impairment of endothelium-dependent pulmonary-Artery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 324(22), 1539-1547 (1991).
139. Lommatzsch M, Cicko S, Muller T et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181(9), 928-934 (2010).
140. 2 receptor-dependent vasorelaxation. Br. J. Pharmacol. 159(3), 576-585 (2010).
141. 2-defcient mice. Br. J. Pharmacol. 147(5), 569-574 (2006).
142. Guns PJ, Korda A, Crauwels HM et al. Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta. Br. J. Pharmacol. 146(2), 288-295 (2005).
143. Ellsworth ML, Sprague RS. Regulation of blood fow distribution in skeletal muscle: role of erythrocyte-released ATP. J Physiol 590(Pt 20), 4985-4991 (2012).
144. Gonzalez-Alonso J. ATP as a mediator of erythrocyte-dependent regulation of skeletal muscle blood fow and oxygen delivery in humans. J. Physiol. 590(Pt 20), 5001-5013 (2012).
145. Kirby BS, Crecelius AR, Voyles WF, Dinenno FA. Impaired skeletal muscle blood fow control with advancing age in humans: attenuated ATP release and local vasodilation during erythrocyte deoxygenation. Circ. Res. 111(2), 220-230 (2012).
146. 6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ. Res. 98(7), 970-976 (2006).
147. Yitzhaki S, Shneyvays V, Jacobson KA, Shainberg A. Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. Biochem. Pharmacol. 69(8), 1215-1223 (2005).
148. Yitzhaki S, Shainberg A, Cheporko Y et al. Uridine-5́-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem. Pharmacol. 72(8), 949-955 (2006).
149. Shainberg A, Yitzhaki S, Golan O, Jacobson KA, Hochhauser E. Involvement of UTP in protection of cardiomyocytes from hypoxic stress. Can. J. Physiol. Pharmacol. 87(4), 287-299 (2009).
150. 2 receptor. Biochem. Pharmacol. 82(9), 1126-1133 (2011).
151. Borna C, Lazarowski E, Van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb. J. 3, 10 (2005).